FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas

Conditions:   Neurofibromatosis 1;   Plexiform Neurofibroma;   NF1 Interventions:   Drug: Test group (Group A): FCN-159 8 mg, orally, once daily;;   Drug: Control group (Group B): Placebo, orally, once daily; Sponsor:   Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials